Related Experiment Video

Updated: Jul 15, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

ABCG1--a potential therapeutic target for atherosclerosis

Zhan-ling Ni1, Shui-ping Zhao, Zhihong Wu

  • 1Department of Cardiology, Second Xiangya Hospital of Central South University, Middle Ren-Min Road No. 86, Changsha, Hunan 410011, PR China. nightingale_ni@hotmail.com

Medical Hypotheses
|April 27, 2007
PubMed

Insights

The ATP-binding cassette transporter G1 (ABCG1) facilitates cholesterol efflux from macrophage foam cells, a key process in reverse cholesterol transport. Enhancing ABCG1 function may offer a novel therapeutic strategy for atherosclerosis.

Area of Science:

  • Biochemistry
  • Cardiovascular Biology
  • Molecular Medicine

Background:

  • Atherosclerosis involves cholesterol accumulation in macrophage foam cells.
  • Reverse cholesterol transport (RCT) is crucial for mitigating this accumulation.
  • Cholesterol efflux from foam cells is a critical, rate-limiting step in RCT.

Purpose of the Study:

  • To investigate the role of ATP-binding cassette transporter G1 (ABCG1) in cholesterol efflux.
  • To determine the contribution of ABCG1 to cholesterol transport to high-density lipoprotein (HDL) particles.
  • To evaluate the therapeutic potential of targeting ABCG1 for atherosclerosis treatment.

Main Methods:

  • Studies on cholesterol efflux from macrophage foam cells.
  • Analysis of ABCG1's interaction with HDL particles.
  • Assessment of ABCG1 overexpression effects on HDL function and cholesterol export.

Main Results:

  • ABCG1 mediates cholesterol export from macrophage foam cells to large HDL particles.
  • ABCG1 accounts for the majority of cholesterol efflux to serum HDL.
  • Overexpression of ABCG1 enhances HDL function by stimulating cholesterol export.

Conclusions:

  • ABCG1 plays a pivotal role in macrophage cholesterol efflux.
  • Targeting ABCG1 represents a promising therapeutic avenue for atherosclerosis.
  • Modulating ABCG1 activity could improve HDL functionality and reduce atherosclerotic burden.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: